glp 1 meds for diabetes How GLP-1 medications are transforming and weight loss treatment New GLP-1 Guidelines for Type

Researchers at the University of Texas first characterized 5-amino-1MQ (5-amino-1-methyl quinolinium) in 2017 while searching for ways to inhibit nicotinamide-N-methyltransferase (NNMT) [1]

Pozo-Rosich, P

Local area network inhibition: a model of a potentially important paraepileptic pathomechanism in neuropsychiatric disorders

Top-line results from the phase 3 ACHIEVE-1 trial for orforglipron for type 2 diabetes were published in April

Higashi, Y

discovered that molybdenum disulfide (MoS2), a highly stable and biocompatible nanomaterial, can effectively support anti-PD-L1 antibodies (aPDL1) and V9302, reduce Gln uptake by tumor cells, and increase the presence of activated CD8+ T cells within tumors